16 September 2026 editorial review · Item
Biolinq Shine: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Biolinq Shine
Scope and findings:
- Read FDA De Novo summary: prescription glucose-range monitor, age 22+, not insulin users, no discrete glucose number or hypoglycemia detection. Confirmed record distinguishes this from insulin-dosing CGM. Launch supply not established.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.